Research programme: phosphodiesterase IV inhibitors - deCODE genetics

Drug Profile

Research programme: phosphodiesterase IV inhibitors - deCODE genetics

Alternative Names: DG 071; PDE4B inhibitors - deCODE genetics; PDE4D inhibitors - deCODE genetics

Latest Information Update: 30 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator deCODE genetics
  • Class Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Suspended Alzheimer's disease; Asthma; Chronic obstructive pulmonary disease; Stroke; Vascular disorders

Most Recent Events

  • 31 Dec 2012 deCODE genetics has been acquired by Amgen
  • 03 Oct 2008 Preclinical trials in Alzheimer's disease in Iceland (unspecified route)
  • 03 Oct 2008 deCODE genetics files an IND application with the FDA in USA for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top